M
Martin Schrappe
Researcher at University of Kiel
Publications - 393
Citations - 26551
Martin Schrappe is an academic researcher from University of Kiel. The author has contributed to research in topics: Minimal residual disease & Childhood Acute Lymphoblastic Leukemia. The author has an hindex of 83, co-authored 355 publications receiving 22797 citations. Previous affiliations of Martin Schrappe include Genomatix.
Papers
More filters
Journal ArticleDOI
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter,Claus R. Bartram,Maria Grazia Valsecchi,André Schrauder,Renate Panzer-Grümayer,Anja Möricke,Maurizio Aricò,Martin Zimmermann,Georg Mann,Giulio Rossi,Martin Stanulla,Franco Locatelli,Giuseppe Basso,Felix Niggli,Elena Barisone,Guenter Henze,Wolf-Dieter Ludwig,Oskar A. Haas,Giovanni Cazzaniga,Rolf Koehler,Daniela Silvestri,Jutta Bradtke,Rosanna Parasole,Rita Beier,Jacques J.M. van Dongen,Andrea Biondi,Martin Schrappe +26 more
TL;DR: Standardized quantitative assessment of minimal residual disease based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD) at 2 time points (TPs) is introduced, to stratify patients in a large prospective study.
Journal ArticleDOI
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui,Jun J. Yang,Stephen P. Hunger,Rob Pieters,Martin Schrappe,Andrea Biondi,Ajay Vora,André Baruchel,Lewis B. Silverman,Kjeld Schmiegelow,Gabriele Escherich,Keizo Horibe,Yves Benoit,Shai Izraeli,Allen Eng Juh Yeoh,Der Cherng Liang,James R. Downing,William E. Evans,Mary V. Relling,Charles G. Mullighan +19 more
TL;DR: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.
Journal ArticleDOI
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
Rob Pieters,Martin Schrappe,Paola De Lorenzo,Ian Hann,Giulio Rossi,Maria S. Felice,Liisa Hovi,Thierry Leblanc,Tomasz Szczepański,Alina Ferster,Gritta Janka,Jeffrey E. Rubnitz,Lewis B. Silverman,Jan Stary,Myriam Campbell,Chi Kong Li,Georg Mann,Ram Suppiah,Andrea Biondi,Ajay Vora,Maria Grazia Valsecchi +20 more
TL;DR: Patients treated with the hybrid protocol, and especially those who responded poorly to prednisone, had higher EFS than most reported outcomes for treatment of infant ALL, and Delayed intensification of chemotherapy did not benefit patients.
Journal ArticleDOI
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Möricke,Alfred Reiter,Martin Zimmermann,Helmut Gadner,Martin Stanulla,Michael Dördelmann,Lutz Löning,Rita Beier,Wolf-Dieter Ludwig,Richard Ratei,Jochen Harbott,Joachim Boos,Georg Mann,Felix Niggli,Andreas Feldges,Günter Henze,Karl Welte,Jörn-Dirk Beck,T. Klingebiel,Charlotte M. Niemeyer,Felix Zintl,U. Bode,Christian Urban,Helmut Wehinger,Dietrich Niethammer,Hansjörg Riehm,Martin Schrappe +26 more
TL;DR: Consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients, and compared without previous trial ALL-BFM 90, consistently favorable results were achieved.
Journal ArticleDOI
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase
Rob Pieters,Stephen P. Hunger,Joachim Boos,Carmelo Rizzari,Lewis B. Silverman,André Baruchel,Nicola Goekbuget,Martin Schrappe,Ching-Hon Pui +8 more
TL;DR: There is an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL and debate on the optimal formulation and dosage of these agents continues.